Novel Alzheimer’s Therapies Given to Less than 20 Percent of Applicants in Japan [Podcast Episode]

By Barrier Free Japan

April 10 2026

TOKYO – Novel Alzheimer’s therapies have been given to 19 pct of outpatients who applied for the medications, according to a recent survey at a Tokyo hospital. The lecanemab and donanemab therapies for early-stage Alzheimer’s patients are now clinically available under Japan’s national health insurance scheme, which curbs a sharp rise in out-of-pocket medical expenses. Despite the relatively low-cost availability, however, the drugs have eventually been administered to only 87 out of 456 applicants, the survey by a study group at the Tokyo Metropolitan Institute for Geriatrics and Gerontology showed.

Episode notes:

‘Novel Alzheimer’s Therapies Given to Less than 20 Percent of Applicants’:

Novel Alzheimer’s Therapies Given to Less than 20 Percent of Applicants